Cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement

Cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement is a genetically defined subtype of bile duct cancer, a malignancy arising from the epithelial cells lining the intrahepatic or extrahepatic biliary tree This oncogenic alteration is most commonly identified in intrahepatic cholangiocarcinoma, occurring in approximately 10% to 15% of cases Pathophysiologically, chromosomal translocations or structural rearrangements fuse the intact kinase domain of ...

Cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement is a genetically defined subtype of bile duct cancer, a malignancy arising from the epithelial cells lining the intrahepatic or extrahepatic biliary tree Clinically, this biomarker defines an aggressive, often locally advanced or metastatic hepatobiliary malignancy characterized by poor conventional systemic chemotherapy outcomes and susceptibility to targeted FGFR kinase inhibition

This oncogenic alteration is most commonly identified in intrahepatic cholangiocarcinoma, occurring in approximately 10% to 15% of cases Pathophysiologically, chromosomal translocations or structural rearrangements fuse the intact kinase domain of *FGFR2* with diverse upstream or downstream partner genes, resulting in ligand-independent receptor dimerization, constitutive FGFR signaling cascade activation, and unchecked neoplastic cell proliferation and survival

This oncogenic alteration is most commonly identified in intrahepatic cholangiocarcinoma, occurring in approximately 10% to 15% of cases Clinically, this biomarker defines an aggressive, often locally advanced or metastatic hepatobiliary malignancy characterized by poor conventional systemic chemotherapy outcomes and susceptibility to targeted FGFR kinase inhibition

Clinically, this biomarker defines an aggressive, often locally advanced or metastatic hepatobiliary malignancy characterized by poor conventional systemic chemotherapy outcomes and susceptibility to targeted FGFR kinase inhibition